Silvan Tuerkcan
Stock Analyst at Citizens
(4.37)
# 358
Out of 5,182 analysts
177
Total ratings
47.7%
Success rate
20.53%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Downgrades: Market Perform | n/a | $52.68 | - | 16 | Mar 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $56.86 | +51.25% | 17 | Dec 23, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.85 | +106.19% | 5 | Nov 20, 2025 | |
| ENGN enGene Therapeutics | Maintains: Market Outperform | $18 → $21 | $7.60 | +176.32% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $14.78 | +42.08% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.71 | +69.85% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $13.25 | +66.04% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $0.93 | +543.50% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $8.60 | +295.35% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $32.35 | +39.10% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $45.86 | +9.03% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $8.23 | +82.26% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.70 | +62.16% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.85 | +85.57% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $15.87 | +656.14% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.64 | +936.59% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.51 | +59.36% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $14.75 | +42.37% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.49 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.16 | +44.23% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $61.69 | +353.88% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.10 | +62.16% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $52.68
Upside: -
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $56.86
Upside: +51.25%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.85
Upside: +106.19%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $7.60
Upside: +176.32%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $14.78
Upside: +42.08%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.71
Upside: +69.85%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $13.25
Upside: +66.04%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $0.93
Upside: +543.50%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $8.60
Upside: +295.35%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $32.35
Upside: +39.10%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $45.86
Upside: +9.03%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $8.23
Upside: +82.26%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.70
Upside: +62.16%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.85
Upside: +85.57%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $15.87
Upside: +656.14%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.64
Upside: +936.59%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.51
Upside: +59.36%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $14.75
Upside: +42.37%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.49
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.16
Upside: +44.23%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $61.69
Upside: +353.88%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.10
Upside: +62.16%